Suppr超能文献

PM20D1 是与阿尔茨海默病相关的一个数量性状位点。

PM20D1 is a quantitative trait locus associated with Alzheimer's disease.

机构信息

Laboratory of Neuroepigenetics, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

Centro Nacional de Análisis Genómico (CNAG), Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

出版信息

Nat Med. 2018 May;24(5):598-603. doi: 10.1038/s41591-018-0013-y. Epub 2018 May 7.

Abstract

The chances to develop Alzheimer's disease (AD) result from a combination of genetic and non-genetic risk factors , the latter likely being mediated by epigenetic mechanisms . In the past, genome-wide association studies (GWAS) have identified an important number of risk loci associated with AD pathology , but a causal relationship remains difficult to establish. In contrast, locus-specific or epigenome-wide association studies (EWAS) have revealed site-specific epigenetic alterations, which provide mechanistic insights for a particular risk gene but often lack the statistical power of GWAS . Here, combining both approaches, we report a previously unidentified association of the peptidase M20-domain-containing protein 1 (PM20D1) with AD. We find that PM20D1 is a methylation and expression quantitative trait locus coupled to an AD-risk associated haplotype, which displays enhancer-like characteristics and contacts the PM20D1 promoter via a haplotype-dependent, CCCTC-binding-factor-mediated chromatin loop. Furthermore, PM20D1 is increased following AD-related neurotoxic insults at symptomatic stages in the APP/PS1 mouse model of AD and in human patients with AD who are carriers of the non-risk haplotype. In line, genetically increasing or decreasing the expression of PM20D1 reduces and aggravates AD-related pathologies, respectively. These findings suggest that in a particular genetic background, PM20D1 contributes to neuroprotection against AD.

摘要

阿尔茨海默病(AD)的发病几率源于遗传和非遗传风险因素的共同作用,后者可能由表观遗传机制介导。过去,全基因组关联研究(GWAS)已经确定了许多与 AD 病理相关的重要风险基因座,但仍难以建立因果关系。相比之下,特定基因座或全基因组范围内的表观遗传关联研究(EWAS)已经揭示了特定的表观遗传改变,这些改变为特定的风险基因提供了机制上的见解,但往往缺乏 GWAS 的统计效力。在这里,我们结合这两种方法,报告了一个以前未被识别的肽酶 M20 结构域包含蛋白 1(PM20D1)与 AD 的关联。我们发现 PM20D1 是一个与 AD 风险相关单倍型相耦合的甲基化和表达定量性状基因座,该单倍型具有增强子样特征,并通过单倍型依赖性、CCCTC 结合因子介导的染色质环与 PM20D1 启动子接触。此外,在 AD 相关神经毒性损伤后,APP/PS1 小鼠模型和携带非风险单倍型的 AD 患者中 PM20D1 的表达增加。相应地,遗传上增加或减少 PM20D1 的表达分别减轻和加重 AD 相关病理。这些发现表明,在特定的遗传背景下,PM20D1 有助于对 AD 的神经保护。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验